Faculty
Patient Care and Research
As academic hematologists our faculty members are active in both patient care and research. Each faculty member has an active clinical practice in Hematology. Our Hematology Clinic at Stanford meets every day. In addition our faculty participates in the Oral Anticoagulation Clinic and we have a very active service at the Veterans Affairs Palo Alto Health Care System.
The faculty has been instrumental in the development and or implementation of clinical trials for many hematologic problems. The mission of the Division of Hematology is carried out by a dedicated group of administrative, clinical and research staff.
Division Chief
Ann Mullally, MD
Division Chief of Hematology
George E. Becker Professor in Medicine
Medicine - Hematology
Dr. Ann Mullally is a physician-scientist and Division Chief of Hematology. She received her MD from University College Dublin, completed residency at Johns Hopkins and fellowship in hematology/oncology in the Brigham/Mass General/Dana-Farber program. Prior to moving to Stanford in 2024, Dr. Mullally was a Principal Investigator at Brigham and Women’s Hospital and a clinical faculty member at Dana-Farber Cancer Institute for approximately 10 years. Dr. Mullally is actively involved in all aspects of patient-oriented research. The overarching goal of her research is to advance the biological understanding of myeloid malignancies and to translate this into improved treatment options for patients dealing with these chronic blood cancers. Dr. Mullally is known as a passionate advocate for physician-scientists in medicine, for her outstanding mentorship of trainees and as a champion of collaborative team science.
- Physician-scientist studying myeloid malignancies.
- Major interests are myeloproliferative neoplasms (MPN) and clonal hematopoiesis (CH) .
- Active areas of research include (i) biology & therapy of mutant calreticulin, (ii) JAK2V617F biology, (iii) clonal expansion of MPN stem cells, (iv) immunological approaches to target MPN.
Faculty
Steven E. Artandi, MD, PhD
Laurie Kraus Lacob Director of the Stanford Cancer Institute (SCI), Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry
Medicine - Hematology
A physician-scientist and oncologist, Dr. Artandi’s research focuses on telomeres and telomerase—key regulators of aging, stem cell function, and cancer. His lab studies how telomere shortening contributes to disease, how cancers exploit telomerase, and how telomerase-expressing stem cells influence tissue renewal and tumor initiation. Clinically, he is dedicated to translating these discoveries into improved cancer detection, prevention, and therapies.
Clinical focus: Hematologic malignancies, solid tumors, translational cancer therapies, novel diagnostics and prevention strategies
Academic focus: Telomere biology, telomerase regulation, stem cell function, cancer initiation, translational oncology research, mentorship in molecular and cancer biology
Caroline Bérubé, MD
Clinical Professor
Medicine - Hematology
Medical Director Outpatient Anticoagulation Clinic
Dr. Berube specializes in thrombosis and rare bleeding disorders, anticoagulation management, and hematologic complications of pregnancy. She is the Medical Director of the Outpatient Anticoagulation Clinic and the Co-Director of the Adult Hemophilia Program at the Stanford Hemophilia Treatment Center.
Clinical focus: classical general hematology, with specific interest in clinical thrombosis and hemostasis, management of anticoagulation, pregnancy-related hematologic conditions, and anemia.
Academic focus: congenital bleeding disorders, clinical trial of gene therapy in hemophilia, and anemia during pregnancy
Ami Bhatt, MD, PhD
Professor of Medicine (Hematology) and of Genetics
Medicine - Hematology
Dr. Ami Bhatt is a Professor in the Departments of Medicine (Hematology; Blood & Marrow Transplantation) and Genetics at Stanford University. She leads a research program focused on microbial genomics, metagenomics, and the development of molecular and computational tools to understand and manipulate the human microbiome.
Clinical focus: Hematologic malignancies, blood and marrow transplantation, genomic approaches in hematology
Academic focus: Microbial genomics, metagenomics, microbiome-host interactions, genome engineering tools, global oncology.
Linda M. Boxer, MD, PhD
Vice Dean of the School of Medicine and Stanley McCormick Memorial Professor
Medicine - Hematology
Dr. Boxer is Vice Dean of Stanford University School of Medicine and the Stanley McCormick Memorial Professor. A Stanford-trained physician-scientist in hematology/oncology, she has led groundbreaking research on B-cell lymphomas and has extensive clinical expertise in hematologic malignancies. She previously served as Chief of Hematology, Interim Chair of Medicine, and Senior Vice Chair, and has trained and mentored generations of physician-scientists. She was appointed Vice Dean in 2013.
Clinical focus: Hematologic malignancies, B-cell lymphomas, patient care in hematology/oncology
Academic focus: B-cell lymphoma research, translational oncology, physician-scientist training and mentorship, leadership in academic medicine
Rondeep Brar, MD
Clinical Professor
Medicine - Hematology
Dr Brar is the Ann & John Doerr Medical Director of the Stanford Cancer Center and Associate Director for Clinical Care at the Stanford Cancer Institute. His clinic includes all types of hematologic disorders, ranging from anemia and clotting/bleeding disorders to complex malignancies such as leukemia, myelodysplastic syndrome, and myeloma.
Clinical Focus: Classical & Malignant Hematology, Paroxysmal Nocturnal Hemoglobinuria
Academic Focus: Health Systems Management, Academic Cancer Care at Scale, Artificial Intelligence
Jason Gotlib, MD
Professor of Medicine (Hematology)
Medicine - Hematology
Dr. Jason Gotlib is Professor of Medicine in the Stanford Division of Hematology. He is Leader of the Hematology Clinical Research Group. Dr. Gotlib's research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, including JAK inhibitors for myelofibrosis, KIT inhibitors for systemic mastocytosis (SM), and targeted agents for eosinophilia.
Clinical focus: Myeloproliferative neoplasms (MPN) including polycythemia vera, essential thrombocythemia, myelofibrosis, and chronic myeloid leukemia; systemic mastocytosis; chronic eosinophilic neoplasms/hypereosinophilic syndrome; myelodysplastic syndrome (MDS), and overlap MDS/MPN disorders.
Academic focus: Clinical trials of novel targeted therapeutics, translational research collaborations
Peter Greenberg, MD
Professor of Medicine, Emeritus
Medicine - Hematology
Dr. Greenberg is Director of the Stanford Myelodysplastic Syndromes Center and has a clinical practice focusing on the evaluation and treatment of MDS and clonal myeloid disorders. His clinical research involves design and coordination of trials using experimental drugs with biologic focus for MDS patients not responding to standard therapies. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS prognostic risk system (the IPSS-R) and the Molecular-IPSS (IPSS-M). He is Chair of the NCCN Practice Guidelines Panel for MDS and is a member of the WHO Clinical Advisory Committee for Myeloid Malignancies.
Clinical Focus: Myelodysplastic Syndromes (MDS), CMML, Clonal hematopoiesis
Academic focus: Clinical trials, hematopoietic biomarkers, outcomes research and translational research collaborations
Calvin J. Kuo, MD, PhD
Maureen Lyles D'Ambrogio Professor
Medicine - Hematology
Dr. Calvin Kuo is the Maureen Lyles D’Ambrogio Professor of Medicine at Stanford University. He leads a research program focused on cancer biology, stem cell biology, and immunology using advanced organoid models and in vivo systems. His lab developed foundational immunocompetent organoid culture systems that have enabled disease modeling, immune-oncology studies, and therapeutic screening.
Clinical focus: Oncology, gastrointestinal cancers, translational cancer therapeutics
Academic focus: Organoid models of cancer, autoimmunity and infection, stem cell niche signaling, tumor immunology, vascular and blood-brain barrier biology, gene editing for disease modeling
Lawrence Leung, MD
Maureen Lyles D'Ambrogio Professor in the School of Medicine
Medicine - Hematology
Dr. Lawrence Leung is a researcher in the field of hematology with a focus on bleeding and thrombotic disorders. His laboratory investigates the molecular mechanisms of coagulation, particularly the role of thrombin and its interactions with key substrates in both hemostasis and inflammation. His recent work explores the link between thrombin-cleaved osteopontin and tumor progression, with efforts underway to translate these findings into novel cancer immunotherapies.
Clinical focus: Bleeding disorders, thrombotic disorders, coagulation abnormalities
Academic focus: Thrombin biology, inflammation, and coagulation, TAFI, cancer immunotherapy
Michaela Liedtke, MD
CKD Family Professor
Medicine - Hematology
Dr. Liedtke is the Clinical Chief of the Division of Hematology, the Director of the Stanford Adolescent and Young Adult Cancer Program and the Co-Director of the Stanford Multidisciplinary Amyloidosis Center. She runs a clinical trial research program in lymphoid malignancies with a focus on acute lymphoblastic leukemia and plasma cell dyscrasias including multiple myeloma and immunoglobulin light chain amyloidosis.
Clinical focus: Acute lymphoblastic leukemia, multiple myeloma, AL amyloidosis
Academic focus: Development and evaluation of novel therapeutic approaches to treat acute lymphoblastic leukemia, multiple myeloma and AL amyloidosis
Ravi Majeti, MD, PhD
Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia and D. K. Ludwig Professor and Professor of Medicine (Hematology/Stem Cell Institute)
Medicine - Hematology
Dr. Majeti was an undergraduate at Harvard, earned his MD and PhD from UCSF, and trained in Internal Medicine at Brigham and Women’s Hospital in Boston. Dr. Majeti completed his Hematology Fellowship at Stanford and is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, where he investigated acute myeloid leukemia (AML) stem cells. Dr. Majeti directs an active NIH-funded laboratory that focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly AML, and has published >120 peer-reviewed articles. He is a recipient of the Burroughs Wellcome Career Award for Medical Scientists, the New York Stem Cell Foundation Robertson Investigator Award, the Leukemia and Lymphoma Society Scholar Award, the Clifford Prize, and the McCulloch and Till Award from the International Society for Experimental Hematology. Dr. Majeti is a member of the American Association for Cancer Research (AACR) Task Force on Hematologic Malignancies. He also serves on the editorial board of Cancer Discovery.
Clinical focus: Hematologic disorders, acute myeloid leukemia (AML), translational therapies targeting leukemia stem cells
Academic focus: Leukemia stem cell biology, molecular characterization of hematologic malignancies, therapeutic targeting strategies, stem cell research, translational oncology
Beverly S. Mitchell, MD
George E. Becker Professor of Medicine, Emerita
Medicine - Oncology
The former Director of the Stanford Cancer Institute and is the George E. Becker Professor of Medicine at Stanford University. Before joining the Stanford faculty, Dr. Mitchell led the Molecular Therapeutics Program at UNC Chapel Hill's Lineberger Comprehensive Cancer Center, where she also served as Associate Director for Translational Research and Chief of the Division of Hematology/Oncology. She has authored over 130 peer-reviewed articles. She served as President of the American Society of Hematology (ASH) and was Chair of the Medical and Scientific Affairs Committee and Vice Chair for Medical and Scientific Affairs of the Leukemia and Lymphoma Society of America.
Clinical focus: Hematologic malignancies, translational cancer therapies, patient care in hematology/oncology
Academic focus: Molecular therapeutics, translational research, hematologic oncology, leadership in professional societies, mentorship and research in blood cancers
Tait Shanafelt, MD
Jeanie and Stew Ritchie Professor
Medicine - Hematology
Dr. Shanafelt is a hematologist at Stanford University who specializes in the treatment of chronic lymphocytic leukemia (CLL), hairy cell leukemia, large granular lymphocytic leukemia (T-cell LGL), and related blood and bone marrow disorders. He leads clinical research focused on the etiology of these conditions, biomarker-driven approaches to personalize treatment, and novel therapies. His work aims to tailor management to the individual based on clinical and molecular characteristics as well as patient preferences.
Clinical Focus: Chronic lymphocytic leukemia (CLL), Hairy cell leukemia, Large granular lymphocytic leukemia (T-cell LGL)
Academic Focus: Disease etiology, Prognostic markers, Development of novel therapies, Evidence-based supportive care
James L. Zehnder, MD
Professor of Pathology (Research) and of Medicine (Hematology)
Medicine - Hematology
Dr. Jim Zehnder is board-certified in Internal Medicine and Hematology. He completed his training and research fellowships at Stanford, where he founded the Stanford Molecular Pathology Laboratory in 1995.
He serves as Director of Clinical Pathology, the Molecular Pathology Fellowship, and the Coagulation Laboratory. His research focuses on the molecular basis of acquired cytopenias, inherited blood disorders, and somatic mutations in cancer. Clinically, he specializes in disorders of thrombosis and hemostasis.
Clinical focus: Disorders of thrombosis and hemostasis, acquired cytopenias, inherited blood disorders
Academic focus: Molecular pathology, somatic mutations in cancer, coagulation research, molecular mechanisms of hematologic disorders, training in molecular pathology
